Omeprazole, widen of Cmax in a normal crossover design? [Design Issues]

posted by wienui  – Germany/Oman, 2016-04-07 13:00 (3729 d 19:29 ago) – Posting: # 16169
Views: 9,003

❝ ❝ “The primary pharmacokinetic variables evaluated for single dose studies were AUC0-t and Cmax and for steady state, AUCτ and Cmax. Bioequivalence was determined based on limits of 80-125% for AUC and 70-143% for Cmax.”


Dear All,

Could we widen the Cmax rang to 70-143% of HVD (Omeprazole) in a normal (not a replicate) 2x2 crossover BE study.

Thanks,

Cheers,
Osama

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
117 visitors (0 registered, 117 guests [including 20 identified bots]).
Forum time: 08:30 CEST (Europe/Vienna)

Scientists often have a naïve faith that
if only they could discover enough facts about a problem,
these facts would somehow arrange themselves
in a compelling and true solution.    Theodosius Dobzhansky

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5